Project description
Risk assessment for diabetes
Type 2 diabetes is a chronic metabolic disorder with an onset in adulthood. It is characterised by high blood sugar levels due to the body's ineffective use or production of the hormone insulin. There is a need to predict individuals with a risk to developing pre-diabetes by detecting insulin resistance and metabolic pathologies at an early stage. To accommodate this, the EU-funded RHAPSODY project will combine clinical information with genetic, biochemical and epigenetic data from several large cohorts of individuals with diabetes across Europe. Moreover, researchers will undertake a comparative analysis across species of the mechanisms underlying diabetes progression. The goal is to identify prognostic and diagnostic biomarkers for improved disease management.
Objective
The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment. To address these goals, RHAPSODY will bring together prominent European experts, including the leaders of the diabetes-relevant IMI1 projects to identify, validate and characterize causal biomarkers for T2D subtypes and progression. Our plans are built upon: (a) access to large European cohorts with comprehensive genetic analyses and rich longitudinal clinical and biochemical data and samples; (b) detailed multi-omic maps of key T2D-relevant tissues and organs; (c) large expertise in the development and use of novel genetic, epigenetic, biochemical and physiological experimental approaches; (d) the ability to combine existing and novel data sets through effective data federation and use of these datasets in systems biology approaches towards precision medicine; and (e) expertise in regulatory approval, health economics and patient engagement. These activities will lead to the discovery of novel biomarkers for improved T2D taxonomy, to support development of pharmaceutical activities, and for use in precision medicine to improve health in Europe and worldwide.
Fields of science
- natural sciencescomputer and information sciencesdatabases
- medical and health sciencesclinical medicinesurgery
- medical and health sciencesclinical medicineendocrinologydiabetes
- natural sciencesbiological sciencesbiochemistrybiomoleculeslipids
- medical and health scienceshealth sciencespersonalized medicine
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
1015 LAUSANNE
Switzerland
See on map
Participants (28)
22100 Lund
See on map
01069 Dresden
See on map
56126 Pisa
See on map
75006 Paris
See on map
75654 Paris
See on map
1050 Bruxelles / Brussel
See on map
1206 Geneve
See on map
OX1 2JD Oxford
See on map
75794 Paris
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
59000 Lille
See on map
70211 KUOPIO
See on map
DD1 4HN Dundee
See on map
SW7 2AZ LONDON
See on map
72074 Tuebingen
See on map
01307 Dresden
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1165 Kobenhavn
See on map
10126 Torino
See on map
9713 GZ Groningen
See on map
59037 Lille
See on map
2333 ZA Leiden
See on map
1025 Saint Sulpice
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
91190 GIF-SUR-YVETTE
See on map
2340 Beerse
See on map
2880 Bagsvaerd
See on map
Participation ended
65929 Frankfurt Am Main
See on map
1081 HV Amsterdam
See on map
RG21 4FA Basingstoke
See on map
9712CP Groningen
See on map